Industry leaders call for greater transparency, enhanced claims oversight, and expanded preventive care, as rising medical costs drive up policyholders’ premiums and insurers’ loss ratios.
New policy addresses management liability needs unique to life sciences, biotech, and pharmaceutical firms and is specifically designed for the R&D ecosystem.
Insurers need to balance hyper-personalisation against the risk of fragmenting risk pools into statistically unreliable segments, industry experts say.